Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma

Lian-Yue Yang, Wei Wang, Ji-Xiang Peng, Jie-Quan Yang, Gen-Wen Huang

INTRODUCTION
Hepatocellular carcinoma (HCC) ranks one of the most common malignancies in the world. Although its morbidity and mortality have decreased recently in patients with surgically treated HCC, the long-term prognosis remains unsatisfactory because of the high recurrence and metastasis rate. Given the complex molecular mechanisms of invasion and metastasis, however, it is generally accepted that the invasive and metastatic potentials of HCC are mostly attributed to the individual clinical pathological and molecular biological characteristics. The diversity of biological characteristics determines the different invasive and metastatic potentials of HCC[4][5]. In our institute, HCC was phenotypically divided into solitary large hepatocellular carcinoma (SLHCC, diameter >5 cm, and one node), nodular hepatocellular carcinoma (NHCC, node number ≥2) and small hepatocellular carcinoma (SHCC, diameter ≤5 cm). Our clinical observation implied different invasive and metastatic abilities between SLHCC and NHCC. To understand the mechanism of different invasive and metastatic potentials between SLHCC and NHCC, the changes in gene expression between SLHCC and NHCC need to be investigated.

Our previous investigations focused on the differentially expressed genes of integrin, matrix metalloproteinases-2 (MMP-2), vascular endothelial growth factor (VEGF), phosphatase and tensin homologue deleted on chromosome ten (PTEN), endoglin (CD105), survivin, which involved in invasion and metastasis, between SLHCC and NHCC[4][5]. Given the complex molecular mechanisms of invasion and metastasis, however, it is not clear that expression of these specific genes alone can explain the diversity of molecular biological characteristics between SLHCC and NHCC. Therefore, a broad evaluation of difference in gene expression between SLHCC and NHCC is necessary.

cDNA microarray represents an important new tool to analyze human gene expression profiles. The technology enables investigators to measure the expression of several thousand mRNAs simultaneously in a biological specimen. It is technically possible to monitor almost the entire transcriptosome, the collection of all mRNAs present in a tumor specimen. cDNA microarray also enables us to study global gene profiles from various samples, thereby to speed up the identification of differentially expressed genes and the construction of different expression profiles. cDNA microarray analysis has become an increasingly popular tool to investigate the function of genes that are responsible for the phenotypes of diseases, to provide potential targets for treatment or prevention[4][5].

Our study was designed to delineate the different expression gene profiles between SLHCC and NHCC from 22 patients to evaluate the difference in gene expression within the realm of 8 464 human genes for understanding the basement of the diversity of molecular biological characteristics between SLHCC and NHCC.

MATERIALS AND METHODS
Tissue specimens
The Ethics Committee of the Central South University approved the study protocol. Fresh surgical HCC was obtained from 22...
(20 males and 2 females) patients, including 7 cases of SLHCC and 15 cases of NHCC with primary hepatocellular carcinoma who underwent hepatectomy at Xiangya Hospital of Central South University (CSU). The specimens were immediately freshly frozen in liquid nitrogen and stored at -80 °C for RNA isolation. The median age of the patients was 52 year (range, 27-73 years). All specimens obtained from surgery resection were confirmed by pathological examination.

**RNA isolation**

Total RNA was extracted from frozen tissue specimens (30-100 mg) using TRIZOL (GIBCO BRL, Gaithersburg, USA) reagent according to the instructions provided by the manufacturer. The quality was checked on 10 g/L agarose gels and the concentration was measured using an ultraviolet spectrophotometer (Biochrom Ltd, Cambridge, England). The uλ wavelength was adjusted at 260 nm.

**Construction of microarray**

Microarray sequences included 8 464 full-length and partial complementary DNAs representing known, novel, and control genes were provided by United Gene Holdings, Ltd, Shanghai, China. The cDNA inserts were amplified by PCR using universal primers to plasmid vector sequences and then purified as described previously[6]. The PCR products were then spotted onto silylated slides (CEL Associates, Houston, TX) using a Cartesian PxSys7500 motion control robot (Cartesian Technologies, Irvine, CA) fitted with Chipmaker micro-spotting technology (TeleChem International, Sunnyvale, CA). After spotting, the slide was exposed to ultraviolet light (65 mj/cm2) for 5 min, rinsed with 2×SSC for 6 h. The slide was dried again and ready for use.

**Probes of expression profile preparation**

Individual RNA specimens from the same group of HCC were mixed equally to obtain 60 µg total RNA. Fluorescent cDNA probes were prepared through reverse transcription and then purified. RNA samples extracted from NHCC were labeled with Cy3-dUTP and those from SLHCC with Cy5-dUTP. The two color probes were then mixed, precipitated with ethanol and dissolved in 20 µL of hybridization solution containing 5×SSC (0.75 mol NaCl and 0.075 mol sodium citrate), 4 g/L SDS, 500 g/L formamide and 5×Denhardt’s solution (1 g/L Ficoll, 1 g/L polyvinylpyrrolidone and 1 g/L bovine serum albumin).

**Hybridization and washing**

Microarrays were prehybridized with hybridization solution containing 5 g/L denatured salmon sperm DNA at 42 °C for 6 h. Fluorescent probe mixture were denatured at 95 °C for 5 min, and the denatured probe mixture were applied onto the prehybridized chip under a cover glass. Chips were hybridized at 42 °C for 18 h. The hybridized chips was then washed at 60 °C for 10 min each in solutions of 2×SSC and 2 g/L SDS, 0.1×SSC and 2 g/L SDS, and 0.1×SSC, then dried at room temperature.

| Gene                  | Primer sequences         | Product size | Annealing temperature |
|-----------------------|--------------------------|--------------|-----------------------|
| RhoC                  | Up 5'-CTTCTCATGTCTTCAGCAAG-3' | 183 bp       | 56 °C                 |
|                       | Down 5'-CTGCAATCCGAAAGAAGCTG-3' |              |                       |
| protocadherin         | Up 5'-GAAGCTTCAAGCTATGAAA-3' | 256 bp       | 52 °C                 |
| LKC                   | Down 5'-CCTTGATTTCTGCACTTC-3' |              |                       |
| β2-MG                 | Up 5'-ACCCCCCACCTGAAAGATGA-3' | 120 bp       | 56 °C                 |
|                       | Down 5'-ATCTTCAAACCTCCATGATG-3' |              |                       |

**Detection and analysis**

The chip was scanned with Scan Array 4000 standard biochip scanning system (Packard Biochip Technologies, Virginia, USA). ImaGene 3.0 software (BioDiscovery, Los Angeles, USA) was used to analyze the intensity of spots. The intensities of each spot at the two wavelengths represented the quantity of Cy3-dUTP and Cy5-dUTP, respectively, hybridized to each spot. The ratio of Cy5 to Cy3 was computed for each location. Overall intensities were normalized with a correction coefficient obtained using the ratios of the housekeeping genes. Genes were identified as differentially expressed if the absolute value of the natural logarithm of the ratio was >0.69. To minimize artifacts arising from low expression values, the genes with raw intensity values for Cy3 and Cy5 >800 counts were chosen for differential analysis.

**RT-PCR**

Total RNA (2 µg) was reversely transcribed in a final 25 µL reaction volume at 37 °C for 1 h by using 200 U M-MULV reverse transcriptase (Promega, Madison, USA). PCR amplification was performed in a final volume of 50 µL containing 5 µL of first strand cDNA solution, 2 U of Taq polymerase (Sangon, Shanghai, China), 5 µL of 10×PCR reaction buffer, 10 µmol/L of dNTP (Sangon, Shanghai, China) and 10 pmol of each 3' and 5' sequence specific oligonucleotide primer (Sangon, Shanghai, China) for RhoC, protocadherin LKC and β2-microglobulin gene (positive control). The amplification was performed on a DNA thermal cycler (Perkin Elmer, Shelton, USA). The primer sequences and the annealing temperature are shown in Table 1. PCR products were electrophoresed on 17 g/L agarose gels. The bands representing amplified products were visualized using ethidium bromide during the exposure to a UV transilluminator. The density of the bands on the gel was quantified by densitometry analysis. The expression of the genes was presented by the relative intensity of the PCR product bands from target sequences to that from the β2-microglobulin gene[7].

**Statistical analysis**

Statistical analysis was performed using the SPSS (version 11.0, Chicago, IL). The nonparametric Mann-Whitney test was performed to evaluate the differences in the expression of RhoC and protocadherin LKC between the groups. P<0.05 was considered statistically significant.

**RESULTS**

**Quality and examination of total RNA**

Ethidium bromide-stained total RNA agarose gel of SLHCC and NHCC was performed (Figure 1). None of our analyzed samples had detectable RNA degradation present at the leading edge of the gel, which is critical for reproducible gene expression data. The productive rate of RNA from SLHCC and NHCC was 0.42-1.64 mg/g and 0.34-1.85 mg/g, respectively. The rate of A260/A280 was 1.81-2.05. These results showed the high quality and purity of total RNA obtained.
Yang LY et al. Differentially expressed genes in HCC

Identification of genes differentially expressed between SLHCC and NHCC

By applying the threshold value of 2 (up-regulation) and 0.5 (down-regulation) for intensity ratio of SLHCC vs NHCC, 668 genes (7.89%) were selected as differentially expressed genes, including 355 up-regulated (4.19%) and 313 down-regulated (3.69%) genes (Figure 2). Consistent with the precision of the assay, scatter plots comparing SLHCC with NHCC showed a wide distribution of the ratio in which red or green spots represented differently expressed genes, while yellow spots were related to similarly expressed genes (Figure 3).

The result revealed that the activated and repressed genes represented a different subset of cellular genes with biochemical activities consistent with the physiology and pathology between SLHCC and NHCC. Collectively, the genes provided a quantitative view of the changes in gene expression that occurred at the level of the human genome between SLHCC and NHCC. Based on the function discrepancy of encoding proteins, these variably expressed genes were mainly divided into 15 classes (Table 2).

Detection mRNA expression of RhoC and protocadherin LKC in SLHCC and NHCC by RT-PCR

Expression of RhoC and protocadherin LKC mRNA was detected in all SLHCC and NHCC. SLHCC tissues revealed significantly higher levels of protocadherin LKC mRNA than NHCC ($P = 0.026$), and showed significantly lower levels of RhoC mRNA than NHCC ($P = 0.031$) (Figure 4). The results were consistent with the results of cDNA microarray.

Table 2 Numbers of variably expressed genes in SLHCC and NHCC

| Class                                                                 | No. of up-regulated genes | No. of down-regulated genes |
|-----------------------------------------------------------------------|----------------------------|-----------------------------|
| Oncogenes and antioncogenes                                           | 6                          | 5                           |
| Genes encoding proteins related to ionic channel and protein transportation | 7                          | 7                           |
| Genes encoding cellular cycle modulator                                | 3                          | 9                           |
| Genes associated with cellular stress                                   | 1                          | 1                           |
| Genes associated with cellular skeleton and movement                    | 5                          | 7                           |
| Genes related to cellular apoptosis                                     | 2                          | 2                           |
| Gene encoding proteins regulating synthesis, repair, and rearrangement of DNA | 0                          | 4                           |
| Genes encoding transcription factors and proteins binding with DNA      | 17                         | 6                           |
| Cytokine receptor gene                                                 | 4                          | 3                           |
| Immunological protein gene                                             | 18                         | 17                          |
| Genes associated with cellular metabolism                              | 32                         | 32                          |
| Genes encoding signal transductional factor                            | 39                         | 31                          |
| Genes encoding factors that regulated protein translation               | 11                         | 37                          |
| Genes encoding proteins that were consistent with body growth and development | 7                          | 8                           |
| Other                                                                 | 203                        | 144                         |
DISCUSSION

Traditional viewpoint insists that the classification and prognosis of HCC are determined by the size of HCC, large HCC is always considered as terminal HCC and unexcisable HCC. However, UICC has changed this opinion in the 6th TNM classification for HCC. The number of nodes, but not the size of HCC, is the crucial factor for classification and prognosis of HCC. It is generally accepted that different HCCs have individual clinical pathological and molecular biological characteristics, which determined the different invasive and metastatic potentials of HCC. Our clinical observation implied different invasive and metastatic abilities between SLHCC and NHCC. As the genomewide expression profile of tumor is a representation of the biology of the tumor, and the diversity in gene expression profile reflects molecular biological diversity, thus, the further investigation of different gene expression profiles between SLHCC and NHCC is anticipated.

In this study, systematic investigation of gene expression patterns between SLHCC and NHCC was performed by using cDNA microarray to understand the mechanism of the diversity of molecular biological characteristics of HCC. A total of 668 genes (7.89%) showed significant change in their expression level between SLHCC and NHCC. It is not surprising that some differentially expressed genes were associated with the progression of HCC and most of them were related to the invasion and metastasis of tumor. These findings lend support to the presence of various molecular characteristics between SLHCC and NHCC. The gene expression profiles also provided a quantitative view of the changes in gene expression that occurred at the level of HCC genome between SLHCC and NHCC. These genes include matrix-degraded gene, cellular skeleton and motion gene, cellular signal and transferring gene, apoptosis-associated gene and so on. Some genes which were propitious to invasion and metastasis were up-regulated and made against these were down-regulated. We focused on matrix-degraded genes, cellular skeleton and motion genes, which were closely related to invasion and metastasis, and selected some of them for further study.

Both cell-cell interaction and cell-stroma interaction play an important role during the invasion and metastasis. Connections through cell-adhesion molecules, integrins, and cadherins stabilize tissue integrity, whereas loss or alteration of these cell surface proteins is associated with increased metastatic potential. The results of our study indicated that cathepsinL (CTSL), integrin$\alpha_6$ (ITGAs) were down-regulated in SLHCC compared with NHCC. We also found that protecadherin LKC gene and H-cadherin gene were overexpressed in SLHCC vs NHCC. CTSL could promote migration of HCC cells through degrading ECM. ITGAs could promote invasion and metastasis of HCC cells through activating MMPs. Loss of H-cadherin expression in invasive cutaneous squamous cell carcinoma suggested it was a potential invasive and metastatic suppressive gene. Protecadherins are a major subfamily of the cadherin superfamilies. This gene is predominantly expressed in liver, kidney and colon tissues, thus designating protecadherin LKC. The expression of protecadherin LKC is markedly reduced in cancers arising from these tissues at both transcriptional and protein levels. When protecadherin LKC was introduced into colon cancer cell line HCT116, which does not express this gene, a significant inhibition of cell proliferation could be observed. Recently, researcher identified the status of protecadherin LKC as an invasion and metastasis suppressor or gene which could increase the coagulation of tumor cells. Our study showed that protecadherin LKC mRNA was down-regulated in NHCC, suggesting a more disperse degree of NHCC cells compared with SLHCC cells.

We also found that many genes associated with cellular skeleton and movement were differentially expressed between SLHCC and NHCC, for instance, RAB34 and RhoC. We focussed on RhoC because it was recently reported to play a crucial role in tumorigenesis. RhoC was found overexpressed in pancreatic ductal adenocarcinomas, and its up-regulation was associated with tumor progression in ovarian carcinomas. Our previous study also showed a significant higher level of RhoC in extrahepatic metastasis of HCC compared with intrahepatic HCC and overexpression of RhoC gene was correlated with vein invasion, number of tumor nodes and extrahepatic metastasis. The expression level of RhoC could reflect the mobility of HCC cells. The results of our study that RhoC was down-regulated in SLHCC compared with NHCC suggested that SLHCC cells had a lower invasive and metastatic potential than NHCC.

Apoptosis is thought to play an important role in the regulation of proliferation of HCC cells. Apoptosis is modulated by a number of gene products which act through protein-protein interactions either as inducers or inhibitors. In our study, the genes of DAP, PHDLA, ATF2, p21 waf1/cip1, and their products which could induce cellular apoptosis, were obviously up-regulated in SLHCC compared with NHCC, whereas survivin, which inhibited cellular apoptosis, was less in SLHCC than in NHCC. These data suggested that one of the mechanisms of SLHCC, which possesses a less invasive and metastatic potential than NHCC, might be a facility in apoptosis of HCC cells. Our study also showed many genes encoding proteins that were consistent with body growth and development were down-regulated in SLHCC compared with NHCC, for instance, SNRPB, NTRK3 and so on. These genes express usually in embryonic tissues and reflect the level of cell differentiation. These results suggested SLHCC cells has a better differentiation than NHCC cells.

In conclusion, the diversity of molecular biological characters between SLHCC and NHCC can be determined by differentially expressed gene profiles. SLHCC shares a better gene phenotype than NHCC, which is consistent with our previous clinical study.

ACKNOWLEDGEMENTS

We are grateful to Zhi-Li Yang, Wei-Qun Lu, Fa-Qing Tang, Jian-Qing Yang and He-Li Liu for their technical assistance.

REFERENCES

1. Okuda K. Hepatocellular carcinoma: clinicopathological aspects. J Gastroenterol Hepatol 1997; 12: 5314-318
2. Huang G, Yang L, Yang J, Liu H, Yang Z. Correlation between epithelial growth factor and overexpression of vascular endothelial growth factor in hepatocellular carcinoma. Zhonghua Zhongliu Zazhi 2002; 24: 546-556
3. Genrich TR, Slonim Dk, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Califiguri MA, Bloomfield CD, Landier ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537
4. Cherepinsky V, Feng J, Rejali M, Mishra B. Shrinkage-based similarity metric for cluster analysis of microarray data. Proc Natl Acad Sci U S A 2003; 100: 9668-9673
5. King HC, Sinha A. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 2001; 286: 2280-2288
6. Schena M. Genome analysis with gene expression microarrays. Bioessays 1996; 18: 427-431
7. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukimoto M. Overexpression of the rHuCo gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998; 77: 147-152
8. Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 2003; 12: 35-50
9. Atkins KB, Treen BR. Phorbol ester stimulated cathepsin L expression in U937 cells. Cell Growth Differ 1995; 6: 713-718
Differentially expressed genes in HCC

Yang LY et al. Differentially expressed genes in HCC 3573

10 Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, Post S. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 2000; 28: 31-39

11 Hourihan RN, O’Sullivan GC, Morgan JG. Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res 2003; 23: 161-165

12 Takeuchi T, Liang SB, Matsuyoshi N, Zhou S, Miyachi Y, Sonobe H, Ohtsuki Y. Loss of T-cadherin (CDH13, H-cadherin) expression in cutaneous squamous cell carcinoma. Lab Invest 2002; 82: 1023-1029

13 Okazaki N, Takahashi N, Kojima S, Masuho Y, Koga H. Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation. Carcinogenesis 2002; 23: 1139-1148

14 Chen MW, Vacherot F, De La Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, Burchardt M, Chopin DK, Buttyan R. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene 2002; 21: 7861-7871

15 Wolverton T, Lalande M. Identification and characterization of three members of a novel subclass of protocadherins. Genomics 2001; 76: 66-72

16 Suzuki ST. Recent progress in protocadherin research. Exp Cell Res 2000; 261: 13-18

17 Horisuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003; 83: 861-870

18 Wang W, Yang LY, Yang ZL, Huang GW, Lu WQ. Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1950-1953

19 Donald CD, Cooper CR, Harris-Hooker S, Emmett N, Scanlon M, Cooke DB 3rd. Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer. Cell Mol Biol 2001; 47: 1033-1038

20 Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001; 114 (Pt 15): 2713-2722

21 Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-535

22 Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG. Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 2000; 149: 775-782

23 Matsumoto H, Nagao M, Ogawa S, Kanehiro H, Hisanaga M, Ko S, Ikeda N, Fujii H, Koyama F, Mukogawa T, Nakajima Y. Prognostic significance of death-associated protein-kinase expression in hepatocellular carcinomas. Anticancer Res 2003; 23: 1333-1341

24 Neef R, Kuske MA, Prols E, Johnson JP. Identification of the human PHLD1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res 2002; 62: 5920-5929

25 Bhumik A, Huang TG, Ivanov V, Gangi L, Qiao RF, Woo SL, Chen SH, Ronai Z. An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest 2002; 110: 643-650

26 el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825

27 Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc’h N, Pold M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEBJ J 2004; 18: 206-208

28 Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K, Miyatake S. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003; 99: 738-745

29 Lo Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna MD, De Rosa G, Kudo Y, Takata T, Altieri DC. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res 2003; 82: 923-928

30 Yang L, Cao Z, Yan H, Wood WC. Coexpression of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003; 63: 6815-6824

31 Grabowski P, Scherubl H. Survivin - an anti-apoptosis protein. Med Sci Monit 2003; 9: LE25

32 Bussey KJ, Lawce HJ, Himoe E, Shu XO, Heerema NA, Perlman EJ, Olson SB, Magenis RE. SNRPN methylation patterns in germ cell tumors as a reflection of primordial germ cell development. Genes Chromosomes Cancer 2001; 32: 342-352

33 Hisao M, Sheng WQ, Tanaka A, Hashimoto H. Gene expression of TrkC (NTRK3) in human soft tissue tumours. J Pathol 2002; 197: 661-667

Edited by Kumar M and Wang XL. Proofread by Xu FM